Executive Summary

Oct 2019
PROSPECTS
Analgesics continue to profit from ban on the sale of antibiotics without prescription

Analgesics continued to see good sales over 2019 thanks to the 2018 ban on selling antibiotics without a prescription. As a result, Saudi consumers continued to use more analgesics whenever they experience pain whether it is due to headaches, fever or inflammation as they can no longer buy antibiotics without going to a doctor and getting a prescription.

Topical analgesics/anaesthetic sees slightly better growth thanks to introduction of new products

Topical analgesics/anaesthetic continued to grow sales over 2019 thanks to the extension of Cigalah’s line to include Deep Freeze spray and patches. Previously, only Deep Heat rubs, patches and sprays were available in Saudi Arabia.

Adult ketoprofen, adult naproxen and OTC triptans likely to come under further regulation in the future

Adult ketoprofen and adult naproxen continued to see modest sales in 2019 as consumers continued to prefer adult aspirin and adult acetaminophen. These remain cheaper per unit than adult naproxen and adult ketoprofen.

COMPETITIVE LANDSCAPE
GSK Consumer Healthcare is new leader following merger

GSK Consumer Healthcare became the new leader in 2019, with this company being created by the global merger of GlaxoSmithKline with Pfizer. This player benefits from offering the wide range of analgesics brands that were previously represented by GlaxoSmithKline, such as Panadol, Voltaren, Solpadeine and Imigran.

Cigalah Group launches new Nurofen variants over 2019

In order to tap into the growth of OTC analgesics over 2019, Reckitt Benckiser Group Plc (RB) via its distributer Cigalah Group launched several Nurofen variants over 2019. These were Nurofen 200mg and 400mg tablets as well as Nurofen for Children 100mg/5ml oral suspension.

SFDA continues to keep an eye on quality in 2019

Despite the improving sales for analgesics over 2019, the SFDA continues to keep an eagle eye on analgesics to make sure that they meet safety regulations. As a result, the SFDA withdrew Julphar Gulf Pharmaceuticals’ Jusprin 81mg and Profinal Suspension 100mg-5ml (100ml) products from the market due to defects in product quality.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Analgesics in Saudi Arabia

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Saudi Arabia with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Saudi Arabia, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Saudi Arabia market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Analgesics in Saudi Arabia?
  • What are the major brands in Saudi Arabia?
  • Are combination products with acetaminophen still popular?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Analgesics in Saudi Arabia - Category analysis

HEADLINES

PROSPECTS

Analgesics continue to profit from ban on the sale of antibiotics without prescription
Topical analgesics/anaesthetic sees slightly better growth thanks to introduction of new products
Adult ketoprofen, adult naproxen and OTC triptans likely to come under further regulation in the future

COMPETITIVE LANDSCAPE

GSK Consumer Healthcare is new leader following merger
Cigalah Group launches new Nurofen variants over 2019
SFDA continues to keep an eye on quality in 2019

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024

Consumer Health in Saudi Arabia - Industry Overview

EXECUTIVE SUMMARY

Higher prices continue to hinder value growth in 2019
Increasing regulation dampens present and future growth
GSK Consumer Healthcare leads thanks to well-known brands and Saudi investment
New players enter internet retailing in 2019 adding new dynamism to the market
Value sales to pick up despite higher prices and expatriates leaving the country

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Distribution of Consumer Health by Format: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format and Category: % Value 2019
Table 15 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches

DEFINITIONS

SOURCES

Summary 1 Research Sources